With the completion of the $8.4 billion acquisition of Synageva BioPharma by a Connecticut pharmaceutical company specializing in marketing extremely rare drugs, the Bay State has one fewer locally-owned, publicly-traded biotech firm. In a statement today, Alexion , which reported 2,273 employees as of the end of last year, said its combination with 282-employee Synageva gives it a new total head count of "more than 2,800 employees."